DiaCarta

United States
Ellsworth, Wisconsin, United States, 94545

Company profile

DiaCarta company profile

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research.

Business identity

Contact email
[email protected]
Phone number
(510) 314-8858
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2011-01-01, Year

Headquarters

Postal code
94545
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$98.2M
Last funding
Series B / $45M / 2018-02-12
Last equity funding
Series B / $45M
Investors
3
Lead investors
2
Founders
2
Articles
47

Founders and investors

Founders

Aiguo ZhangPaul Okunieff

Lead investors

BVCFFortune Fountain Capital

Investors

BVCFFortune Fountain CapitalGood Health Capital(GHC)